Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Quarterly Report · 10-Q

Oramed Pharmaceuticals Inc.

ORMPNASDAQEQUITYCurrent

Quarterly Report

Filed Aug 10, 2026Accepted Aug 10, 2026, 5:29 PM EDTCIK 1176309Accession 0001213900-26-087361
Share

Company context

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) is a clinical-stage pharmaceutical company and platform technology pioneer in oral delivery solutions for drugs currently delivered via injection. Oramed’s Protein Oral Delivery (POD™) technology is designed to protect drug integrity and increase absorption. Oramed is building a diversified active investment portfolio while advancing its refined oral insulin program.

Current securities

Recent company filings

  1. Submission of Matters to a Vote of Security HoldersSep 17, 2026
  2. SCHEDULE 13G/A filingAug 14, 2026
  3. ARS filingAug 3, 2026
  4. DEFA14A filingAug 3, 2026
  5. DEF 14A filingAug 3, 2026

As-filed source

Primary evidence